Effect of budesonide combined with montelukast on inflammatory factors and immune function in children with bronchial asthma
Shi Xian
Yu Feng
Abstract：Objective To investigate the effect of budesonide combined with montelukast on inflammatory factors and immune function in children with bronchial asthma.Methods A total of 96 children with bronchial asthma were enrolled from July 2015 to June 2016 in our Hospital;they were randomly divided into observation group and control group,with 48 cases in each group.The control group had budesonide inhalation therapy;the observation group took montelukast on the basis of control group;both groups were treated for 4 months.Clinical efficacy,levels of serum inflammatory factors and T lymphocyte subsets were analyzed.Results The total effective rate in observation group was significantly higher than that in control group[93.7％ (45/48) vs 79.2％ (38/48)] (x2 =4.360,P =0.015).After 4 months of treatment,levels of serum intedeukin-6,tumor necrosis factor-α,high-sensitivity C-reactive protein,CD4+ and CD4+/CD8+ in observation group were significantly lower than those in control group [(45 ± 6) ng/L vs (78 ± 9) ng/L,(8.2 ± 1.1) ng/L vs (13.4 ± 1.4) ng/L,(8.0 ± 1.1)mg/L vs (11.3 ± 1.2)mg/L,(45 ±5)％ vs (48 ±6)％,(1.13 ±0.24) vs (1.35 ±0.28)];levels of CD3+ and CD8+ in observation group were significantly higher than those in control group [(67 ± 7) ％ vs (63 ± 7) ％,(40 ± 5) ％ vs (36 ± 4) ％] (P ＜ 0.05).Conclusion Budesonide combined with montelukast can help improve clinical efficacy of children with bronchial asthma,which may be related to alleviating inflammatory response and regulating immune function.
Keywords：Bronchial asthmaBudesonideMontelukastInflammatory factorsT lymphocyte subsets
Publication Date：2018-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 55-58 )